Citigroup maintains Zimmer Biomet Holdings at Neutral, raises price target to $117 from $99

Citigroup kept its Neutral rating on Zimmer Biomet (ZBH) but raised its price target to $117 from $99, suggesting a 9.5% upside from the Nov 5 close of $106.85. Recent analyst price targets for ZBH range from $100 to $125.

Original reporting
Published Nov 5, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains Zimmer Biomet Holdings at Neutral, raises price target to $117 from $99 — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

A higher price target can prompt short-term buying pressure, though impact may be modest without accompanying fundamentals.

02

Market read

Analyst target raise provides a modest catalyst for ZBH, potentially influencing short‑term price action.

03

What to watch

No new product or earnings data accompanies the upgrade.

Relevance 6/10Novelty 6/10Timing: today

Background

The article reports a recent analyst action by Citigroup on Zimmer Biomet Holdings.

Company-level read

Ticker impact

$ZBHBullishMedium confidence
Context

Citigroup raised its price target on Zimmer Biomet Holdings to $117 from $99.

Expected impact

upward pressure as market prices in higher target

Evidence & confidence

Target increase signals improved outlook, likely to attract buying interest.

Market effects

May lift sentiment for orthopedic device sector.

U.S. healthcare equities could see modest gains.

Limited to investors tracking medical device stocks.

Counterpoint

Target raise may already be priced in; price could stall.

Key entities

  • Zimmer Biomet Holdings

    Medical device manufacturer (ticker ZBH).

  • Citigroup

    Equity research analyst raising price target.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.